Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05636943 · ClinicalTrials.gov registry record · NA
Couples' QOL in Metastatic Breast Cancer
A NA study of Metastatic Breast Cancer, sponsored by Fox Chase Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 1
- Study location
NCT05636943: Active NA study of Metastatic Breast Cancer, sponsored by Fox Chase Cancer Center.
NCT05636943 is a NA study of Metastatic Breast Cancer that is active but no longer recruiting, run by Fox Chase Cancer Center. The registered enrollment target is 110 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05636943, a NA study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Fox Chase Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objectives of this study are to adapt and evaluate a sexual quality of life intervention in women with metastatic breast cancer and their partners.
Primary Outcome
Patients' self-reported sexual function will be measured using the 19-item Female Sexual Function Index (FSFI).Total scale scores range from 2 to 36, with higher scores indicating higher functioning. Mean change scores will be reported: positive mean change scores indicate increase in sexual functioning over time while negative mean change scores indicate decrease in sexual functioning over time.
Conditions Studied
Interventions
- BEHAVIORAL Adapted Intimacy Enhancement
- BEHAVIORAL Intimacy Facts and Resources
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2021-01-01 |
| Est. Completion | 2025-05-30 |
| Phase | NA |
What the registry record for NCT05636943 still lists
NCT05636943 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (46% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Adapted Intimacy Enhancement is the first listed.
NCT05636943 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05636943 about?
NCT05636943 is a clinical study titled "Couples' QOL in Metastatic Breast Cancer". The primary objectives of this study are to adapt and evaluate a sexual quality of life intervention in women with metastatic breast cancer and their partners.
What is the current status of trial NCT05636943?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2021-01-01. Estimated completion is 2025-05-30.
What conditions does trial NCT05636943 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT05636943?
The interventions under investigation include: Adapted Intimacy Enhancement (BEHAVIORAL), Intimacy Facts and Resources (BEHAVIORAL).
Who is sponsoring clinical trial NCT05636943?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05636943 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05636943's enrollment target sits among peer trials
110 59th of 139 higher than 80 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Adaptation of a Values Assessment Tool
RECRUITING · NA
-
Every Day Counts: A Lifestyle Program for Women With Metastatic Breast Cancer
RECRUITING · NA
-
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
RECRUITING · NA
-
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
RECRUITING · NA
-
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03190941 · 110 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI